GlassScriptPhysician profile
Letitia L Anderson
NPI 1700946019
$1,644.80
in general payments reported to CMS, 2019-2025
20 companies · $301 in 2025
The $301 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.03 · 2020: $29.18 · 2021: $311 · 2022: $390 · 2023: $398 · 2024: $128 · 2025: $301.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $828.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $827.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $342.77 | 2022-2023 | Micra, Linq II |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $237.45 | 2022-2024 | Lifevest |
| Novartis Pharmaceuticals Corporation | $190.88 | 2023-2025 | |
| Abbott Laboratories | $158.78 | 2021 | |
| Heartflow, INC. | $98.23 | 2025 | |
| Merck Sharp & Dohme LLC | $81.17 | 2021-2024 | Verquvo |
| Edwards Lifesciences Corporation | $78.94 | 2025 | Sapien 3 Ultra Resilia |
| Boston Scientific Corporation | $77.18 | 2020-2022 | |
| Abbvie INC. | $74.58 | 2019 | |
| Janssen Pharmaceuticals, INC | $74.07 | 2021-2023 | Xarelto |
| Alnylam Pharmaceuticals INC. | $55.01 | 2025 | Amvuttra |
| Madrigal Pharmaceuticals | $53.57 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $24.44 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $20.05 | 2023 | Inpefa |
| Astrazeneca Pharmaceuticals LP | $16.96 | 2024 | Farxiga |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotronik INC. | $15.96 | 2023 | Acticor 7 Vr-T Dx |
| Lucid Diagnostics INC. | $15.04 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $12.45 | 2019 | |
| Kiniksa Pharmaceuticals, LTD. | $11.61 | 2021 | |
| Cardiovascular Systems INC. | $5.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Letitia Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.